Overall neuro-ophthalmological outcomes
| Study | Symptom onset to treatment (mean±SD) | Patients with NOS* and F/U | NOS F/U (mean±SD) | Complete recovery | Partial recovery | Improvement (complete and partial recovery) | No change | Transient worsening | Permanent worsening |
| Yu et al22 | NR | 13 | 3.5 months (median) | 10/13 (76.9%) | 0 (0%) | 10/13 (76.9%) | 3/13 (23.1%) | 0/13 (0%) | 0 (0%) |
| Szikora et al28 | NR | 16 | NR | 10/16 (62.5%) | 5/16 (31.3%) | 15/16 (93.8%) | 0/16 (0%) | 3/16 (18.8%) | 1/16 (6.3%) |
| O’Kelly et al26 | NR | 27 | NR | 12/27 (44.4%) | 6/27 (22.2%) | 18/27 (66.7%) | 9/27 (33.3) | 2/27 (7.4%) | 0/27 (0%) |
| Moon et al35 | 50.4 weeks (mean) | 19 | 9.7±6.3 months | 3/19 (15.8%) | 11/19 (57.9%) | 14/19 (73.7%) | 5/19 (26.3%) | 2/19/10.5%) | 0/19 (0%) |
| Tanweer et al37 | NR | 19 | NR | NR | NR | 16/19 (84.2%) | 3/19 (15.8%) | 0/19 (0%) | 0/19/0%) |
| Zanaty et al34 | NR | 51 | NR | 36/51 (70.6%) | 11/51 (21.6%) | 47/51 (92.2%) | 4/51 (7.8%) | 0/51 (0%) | 0/51 (0%) |
| Zhou et al38 | NR | 11 | NR | 4/11 (36.4%) | 4/11 (36.4%) | 8/11 (72.7%) | 3/11 (27.3%) | 2/11 (18.2%) | 0/11 (0%) |
| Puffer et al31 | NR | 20 | 10.3±7.6 months | 18/20 (90%) | 0/20 (0%) | 18/20 (90%) | 2/20 (10%) | 2/20 (10%) | 0/20 (0%) |
| Sahlein et al46 | NR | 39 | 6 months | 2/39 (5.1%) | 22/39 (56.4%) | 24/39 (61.5%) | 13/39 (33.3%) | 0/39 (0%) | 2/39 (5.1%) |
| Zanaty et al45 | NR | 12 | NR | 9/12 (75%) | 3/12 (25%) | 12/12 (100%) | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Breu et al49 | NR | 9 | NR | NR | NR | 6/9 (66.7%) | 3/9 (33.3%) | 0/9 (0%) | 0/9 (0%) |
| Kim et al53 | NR | 18 | NR | NR | NR | 15/18 (83.3%) | 3/18 (16.7%) | 15/18 (83.3%) | 0/18 (0%) |
| Brown et al54 | 11 within 4 weeks, 27 beyond | 45 | 8.4 months | 19/45 (42.2%) | 11/45 (24.4%) | 30/45 (66.6%) | 14/45 (31.1%) | 0/45 (0%) | 1/45 (2.2%) |
| Miyachi et al64 | NR | 18 | 3–6 months | 6/18 (33.3%) | 10/18 (55.6%) | 16/18 (88.9%) | 2/18 (11.1%) | 8/18 (44.4%) | 0/18 (0%) |
| Silva et al71 | NR | 15 | NR | NR | NR | 14/15 (93.3%) | 1/15 (6.7%) | 0/15 (0%) | 0/15 (0%) |
| Oishi et al73 | NR | 38 | 13.5 months | NR | NR | 18/38 (47.4%) | 17/38 (44.7%) | 3/38 (7.9%) | 0/38 (0%) |
| Yan et al79 | NR | 50 | 6–33 months | 31/50 (62%) | 12/50 (24%) | 43/50 (86%) | NR | NR | NR |
| Wang et al76 | 11 within 4 weeks, 11 beyond | 21 | 25.5±1.7 months | 6/21 (28.6%) | 6/21 (28.6%) | 12/21 (57.1%) | 5/21 (23.8%) | 0/21 (0%) | 4/21 (19%) |
| Boulouis et al7 | 16.2±7.6 weeks | 54 | 13.2±10.4 months | 19/54 (35.2%) | 18/54 (33.3%) | 37/54 (68.5%) | 10/54 (18.5%) | 0/54 (0%) | 3/54 (5.6%) |
| Fujii et al93 | NR | 29 | 36 months | NR | NR | 20/29 (69%) | 7/29 (24.1%) | 0/29 (0%) | 2/29 (6.9%) |
| Xu et al95 | 8 weeks (median) | 26 | NR | NR | NR | 20/26 (76.9%) | 6/26 (23.1%) | 0/26 (0%) | 0/26 (0%) |
| Lee et al94 | NR | 28 | NR | NR | NR | 15/28 (53.6%) | NR | NR | NR |
*NOS=neuro-ophthalmological symptoms induced by internal carotid artery aneurysm, treated with flow diversion.
F/U, follow-up; NR, not reported.